Optimized expression cassette for expressing a polypeptide with high yield

ABSTRACT

The present invention is based on the finding that the combination of a specific 5′UTR polynucleotide sequence (see SEQ ID NO 1) and the hCD33 secretory leader sequence in an expression cassette for expressing a polypeptide of interest results in a surprisingly better expression level of the polypeptide of interest compared to prior art expression cassettes. Based on this finding, the present invention inter alia provides novel expression cassettes, expression vectors and methods for producing a polypeptide of interest with high yield.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Feb. 25, 2016, isnamed PAT055302-US-PCT_SL.txt and is 7,637 bytes in size.

FIELD OF THE INVENTION

The present invention inter alia relates to an expression cassettesuitable for expressing a polypeptide of interest wherein saidexpression cassette comprises a combination of a specific 5′UTR and thehCD33 secretory leader sequence. It was found that this specificcombination of genetic elements surprisingly results in a significantbetter expression level of the polypeptide of interest compared tocombinations of other 5′UTRs with other secretory leader sequences.Therefore, using this expression cassette is advantageous for producinga polypeptide of interest with high yield.

BACKGROUND OF THE INVENTION

The ability to clone and express a polypeptide of interest in largeamounts has become increasingly important. The ability to produce andpurify high levels of proteins is in particular important in the humanpharmaceutical and biotechnological field, for example for producingprotein pharmaceuticals as well as in the basic research setting, forexample for crystallizing proteins to allow the determination of theirthree dimensional structure. Proteins that are otherwise difficult toobtain in quantity can be over-expressed in a host cell and subsequentlyisolated and purified.

The choice of an expression system for the production of recombinantproteins depends on many factors, including cell growth characteristics,expression levels, intracellular and extracellular expression,post-translational modifications and biological activity of the proteinof interest, as well as regulatory issues and economic considerations inthe production of therapeutic proteins. Key advantages of mammaliancells over other expression systems such as bacteria or yeast are theability to carry out proper protein folding, complex N-linkedglycosylation and authentic O-linked glycosylation, as well as a broadspectrum of other post-translational modifications. Due to the describedadvantages, eukaryotic and in particular mammalian cells are currentlythe expression system of choice for producing complex therapeuticproteins such as monoclonal antibodies.

The most common approach to obtain high expressing host cells (alsocalled high producers) is to generate an appropriate expression vectorfor expressing the product of interest as a first step. The expressionvector drives the expression of the polynucleotide encoding the productof interest in the host cell and usually comprises at least oneselectable marker for generating the recombinant cell line. Expressionvectors used for expressing a polypeptide in a host cell usuallycomprise besides the polynucleotide encoding the protein of interesttranscriptional control elements suitable to drive transcription such ase.g. promoters, enhancers, polyadenylation signals, transcriptionpausing or termination signals as element of an expression cassette.Furthermore, suitable translational control elements are usuallyincluded and operably linked to the polynucleotides to be expressed,such as e.g. appropriate 5′UTRs and 3′ UTRs.

To increase the efficiency of such an expression system, differentelements are optimized, especially the DNA sequences which contribute tothe efficiency of transcription and translation, protein synthesis,correct folding in ER and protein secretion. High yielding expressionsystems without optimized translation and secretion components couldpotentially lead to mRNA instability, insufficient protein secretion,and miss-folded (inactive) protein accumulation in the cell cytosol ormembrane. Therefore, expression systems enabling stable and consistenttranslation and secretion of correctly folded proteins into the cellculture medium are of particular interest. Such secretory systems offerthe advantages of a stable and efficient mRNA translation; correctprotein folding and efficient secretion, simple and fast productpurification procedures, as well as an increased yield compared tocytosolic systems. However, the product yields of the majority of theavailable secretory systems are not yet fully optimized. To improve theproductivity and secretion efficiency, one aim is to optimize thesecretion signals (also referred to herein as signal peptide orsecretory leader sequence), as well as their combination with different5′UTR sequences in order to obtain a combination of genetic elementsthat results in the desired high level expression.

The majority of secreted and membrane-bound proteins from eitherprokaryotic or eukaryotic organisms possess an amino-terminal leaderpeptide (also referred to as secretory leader sequence or signalpeptide) that is cleaved from the nascent precursor polypeptide duringbiosynthesis. Secretory leader peptides are usually 5 to 60 amino acidslong. This sequence is necessary and sufficient for secretion. Analysisof a large number of these secretory leader peptides has revealed acommon structural motif that occurs in the absence of significant aminoacid sequence homology [Von Heijne, 1981; Perlman et al, 1983]. Ingeneral, a secretory leader sequence consists of a positively chargedamino terminus (n), a hydrophobic core (h) and a more polar carboxyterminus (c) that defines the signal peptidase cleavage site. The “n”region of the secretory leader peptide is about 5 to 8 amino acids longand is characterized by the presence of basic residues. The “h” regioncontains 8 to 12 non-polar amino acids that are composed in average of37% leucine, 15% alanine, 10% valine, 10% phenylalanine, 7% isoleucineand 21% hydrophobic amino acids such as glycine, methionine, proline ortrytophane. This region has a high propensity for alpha-helix formation,a conformation which may facilitate interaction with the interior of thelipid bilayer. Studies on the structural features of secretory leaderpeptides, primarily based on bacterial proteins, have suggested that the“h” region is critical to signal sequence function [Gierasch, 1990].Disruption of the h region by deletion or by replacement of hydrophobicresidues with hydrophilic or charge amino acids leads to loss of signalfunction, whereas alterations to the “n” region have little effect [Birdet al, 1990]. The carboxy terminus, or cleavage region, is typicallyabout 6 amino acids long. This region is involved in signal peptidaserecognition and cleavage, which is usually required to achieve finalfolding and secretion of the protein.

The 5′ UTR (5′ untranslated region) is a part of a DNA sequence that istranscribed into mRNA, but not into protein. It usually begins at thetranscription initiation, and ends one nucleotide before the startcodon. A 5′UTR may contain sequences that regulate the translationefficiency or mRNA stability, binding sites for proteins, regulatoryelements, and sequences that promote the initiation of translation.5′UTR sequences can vary in their length and may comprise a few tenthsof nucleotides up to few hundreds or even several thousand nucleotides.In eukaryotes, the median length of the 5′UTR is approximately 100 to200 nt. The specific role of the 5′UTR and its elements has not beenfully elucidated yet, partially also because the sequence is nottranslated into functional protein. However, it is known that thecombination of a specific 5′UTR and a specific secretory leader sequencecan strongly improve the translation and secretion efficiency of theproduction system and thus may increase the expression yield. However,as a plethora 5′UTRs and secretory leader sequences are available, it isa challenge to obtain an efficient combination that indeed improves theexpression. Thus, despite the plethora of available expression cassettesand expression vectors, obtaining a robust polypeptide/proteinproduction with a high yield in eukaryotic cells is still challenging.

Therefore, it is the object of the present invention to provide anexpression cassette that enables the secretion of a polypeptide ofinterest with high yield when said expression cassette is introducedinto a host cell. Furthermore, it is an object of the present inventionto provide an expression vector that allows for the expression of apolypeptide of interest with high yield. Furthermore, it is an object ofthe present invention to provide a method suitable for expressing apolypeptide of interest with high yield.

SUMMARY OF THE INVENTION

The present invention is based on the finding that combining a specific5′UTR polynucleotide sequence (see SEQ ID NO 1, which is also containedin SEQ ID NO 2, 3 and 4 and also 5, 6 and 7) and the human CD33secretory leader sequence in an expression cassette results in asurprisingly high expression of the polypeptide of interest that isencoded by said expression cassette. In several examples, it was shownthat the expression cassette according to the present invention issuperior over expression cassettes known in the prior art because theexpression yield could be increased up to 4 fold. The superiorperformance of the expression cassette according to the presentinvention was confirmed in numerous experiments wherein differentpolypeptides of interest were expressed from said expression cassette.Therefore, the expression cassette according to the present invention isparticularly advantageous for producing a polypeptide of interest withhigh yield. Additionally, it was found that the correct processing ofthe leader sequence may be improved. Hence, the present inventionprovides a valuable contribution to the art because this novel design ofthe expression cassette considerably improves the expression of thepolypeptide of interest.

According to a first aspect, the present invention provides anexpression cassette for expressing a polypeptide of interest comprising:

-   -   a) a promoter    -   b) a 5′UTR polynucleotide sequence, wherein said 5′UTR        polynucleotide sequence is selected from the group consisting of        -   i) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 1) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgca;

-   -   -   ii) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 2) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cg;

-   -   -   iii) a 5′UTR polynucleotide sequence comprising the            following sequence

(SEQ ID NO 3) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtccacc;

-   -   -   iv) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 4) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgcgattgaattccccggggatcctctagggtgaccgtttggtgccgcca cc;

-   -   -   v) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 5) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaacgcgcctctagagccgccacc;

-   -   -   vi) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 6) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaaacgcgtgccgccacc;

-   -   -   vii) a 5′UTR polynucleotide sequence comprising the            following sequence

(SEQ ID NO 7) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtgccgccacc;

-   -   -   viii) a 5′UTR polynucleotide sequence comprising a sequence            that is at least 85%, preferably at least 90% identical to a            sequence shown in SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or            SEQ ID NO 4 or SEQ ID NO 5, SEQ ID NO 6 or SEQ ID NO 7;

    -   c) a polynucleotide encoding a hCD33 secretory leader sequence;        and

    -   d) a polynucleotide encoding a polypeptide of interest or an        insertion site for inserting a polynucleotide encoding a        polypeptide of interest.

According to a second aspect, the present invention provides anexpression vector for expressing a polypeptide of interest, comprisingat least one expression cassette according to the first aspect of thepresent invention.

According to a third aspect, the present invention provides a eukaryotichost cell which comprises at least one expression cassette according tothe first aspect of the present invention and/or at least one expressionvector according to the second aspect of the present invention.

According to a fourth aspect, the present invention provides a methodfor producing the host cell according to the third aspect of the presentinvention, wherein an expression vector according to the second aspectof the present invention is introduced into a eukaryotic host cell.

According to a fifth aspect, the present invention provides a method forproducing a polypeptide of interest, said method comprising theculturing of host cells according to the third aspect of the presentinvention in a cell culture under conditions allowing the expression ofsaid polypeptide of interest.

According to a sixth aspect, the present invention pertains to the useof a 5′UTR sequence in combination with a hCD33 secretory leadersequence in an expression cassette for expressing a polypeptide ofinterest with high yield from said expression cassette, wherein said5′UTR polynucleotide sequence is selected from the group consisting of

-   -   i) a 5′UTR polynucleotide sequence comprising the sequence

(SEQ ID NO 1) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgca;

ii) a 5′UTR polynucleotide sequence comprising the following sequence

(SEQ ID NO 2) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cg;

-   -   iii) a 5′UTR polynucleotide sequence comprising the following        sequence

(SEQ ID NO 3) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtccacc;

-   -   iv) a 5′UTR polynucleotide sequence comprising the following        sequence

(SEQ ID NO 4) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgcgattgaattccccggggatcctctagggtgaccgtttggtgccgcca cc;

-   -   v) a 5′UTR polynucleotide sequence comprising the following        sequence

(SEQ ID NO 5) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaacgcgcctctagagccgccacc;

-   -   vi) a 5′UTR polynucleotide sequence comprising the following        sequence

(SEQ ID NO 6) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaaacgcgtgccgccacc;

-   -   vii) a 5′UTR polynucleotide sequence comprising the following        sequence

(SEQ ID NO 7) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtgccgccacc;

-   -   viii) a 5′UTR polynucleotide sequence comprising a sequence that        is at least 85%, preferably at least 90% identical to a sequence        shown in SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or SEQ ID NO 4 or        SEQ ID NO 5, SEQ ID NO 6 or SEQ ID NO 7.

Other objects, features, advantages and aspects of the presentapplication will become apparent to those skilled in the art from thefollowing description and appended claims. It should be understood,however, that the following description, appended claims, and specificexamples, while indicating preferred embodiments of the application, aregiven by way of illustration only. Various changes and modificationswithin the spirit and scope of the disclosed invention will becomereadily apparent to those skilled in the art from reading the following.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an expression cassette for expressing apolypeptide of interest comprising a novel combination of geneticelements, namely a specific 5′UTR polynucleotide sequence and the hCD33secretory leader sequence. This specific combination of genetic elementsresults in a significant increase in the expression efficiency of theencoded polypeptide of interest. Furthermore, it was found that theprocessing of the leader sequence may be improved so that unwantedsequence extensions or truncations (also known as “clipping”) due toerroneous processing of the leader sequence can be reduced.

According to a first aspect, an expression cassette is provided forexpressing a polypeptide of interest comprising:

-   -   a) a promoter    -   b) a 5′UTR polynucleotide sequence, wherein said 5′UTR        polynucleotide sequence is selected from the group consisting of        -   i) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 1) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgca;

-   -   -   ii) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 2) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cg;

-   -   -   iii) a 5′UTR polynucleotide sequence comprising the            following sequence

(SEQ ID NO 3) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtccacc;

-   -   -   iv) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 4) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgcgattgaattccccggggatcctctagggtgaccgtttggtgccgcca cc;

-   -   -   v) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 5) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaacgcgcctctagagccgccacc;

-   -   -   vi) a 5′UTR polynucleotide sequence comprising the following            sequence

(SEQ ID NO 6) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaaacgcgtgccgccacc;

-   -   -   vii) a 5′UTR polynucleotide sequence comprising the            following sequence

(SEQ ID NO 7) agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtgccgccacc;

-   -   -   viii) a 5′UTR polynucleotide sequence comprising a sequence            that is at least 85%, preferably at least 90% identical to a            sequence shown in SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or            SEQ ID NO 4 or SEQ ID NO 5, SEQ ID NO 6 or SEQ ID NO 7;

    -   c) a polynucleotide encoding a hCD33 secretory leader sequence;        and

    -   d) a polynucleotide encoding a polypeptide of interest or an        insertion site for inserting a polynucleotide encoding a        polypeptide of interest.

The term “expression cassette” as used herein in particular refers to aDNA segment that is capable in an appropriate setting of driving theexpression of a polynucleotide encoding a polypeptide of interest thatis incorporated in said expression cassette. When introduced into a hostcell, an expression cassette inter alia is capable of directing thecell's machinery to transcribe an incorporated polynucleotide encoding apolypeptide of interest into RNA, which is then usually furtherprocessed and finally translated into the polypeptide of interest. Theexpression cassette can be comprised in an expression vector as will bedescribed in further detail below. The individual elements of theexpression cassette according to the present invention are subsequentlyexplained in detail.

The expression cassette according to the present invention comprises aselement a) a promoter. The term “promoter” as used herein in particularrefers to a DNA element that facilitates the transcription of apolynucleotide the promoter is operably linked to. The promoter may alsoform part of a promoter/enhancer element. Although the physicalboundaries between the elements “promoter” and “enhancer” are not alwaysclear, the term “promoter” usually refers to a site on the nucleic acidmolecule to which an RNA polymerase and/or any associated factors bindsand at which transcription is initiated. Enhancers potentiate promoteractivity, temporally as well as spatially. Many promoters are known inthe prior art that are transcriptionally active in a wide range of celltypes. Promoters can be divided in two classes, those that functionconstitutively and those that are regulated by induction orderepression. Both classes are suitable for protein expression.Promoters that are used for high-level production of polypeptides ineukaryotic and in particular mammalian cells should be strong andpreferably should be active in a wide range of cell types. Strongconstitutive promoters which are capable of driving the expression inmany cell types are well known in the prior art and thus, need no todetailed description here. Preferably, a cytomegalovirus (CMV) promoteris used according to the teachings of the present invention. A promoteror promoter/enhancer derived from the immediate early (IE) region of thehuman cytomegalovirus (hCMV) is particularly suitable as promoter in theexpression cassette according to the present invention. The immediateearly (IE) region of the human cytomegalovirus (hCMV) and functionalexpression promoting fragments and/or functional expression enhancingfragments derived therefrom are e.g. described in EP 0 173 177 and EP 0323 997 and are also well-known in the prior art. Thus, severalfragments of the immediate early (IE) region of hCMV can be used aspromoter and/or promoter/enhancer. According to one embodiment a humanCMV promoter is used in the expression cassette according to the presentinvention. The term “a human CMV promoter” as used herein in particularrefers to a promoter that is derived from the immediate early (IE)region of hCMV.

According to one embodiment, a human CMV promoter is used which isselected from the group consisting of:

-   -   a) a promoter comprising the following sequence

(SEQ ID NO 8) tcaatattgg ccattagcca tattattcat tggttatata gcataaatcaatattggcta ttggccattg catacgttgt atctatatca taatatgtac atttatattggctcatgtcc aatatgaccg ccatgttggc attgattatt gactagttat taatagtaatcaattacggg gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacggtaaatggccc gcctggctga ccgcccaacg acccccgccc attgacgtca ataatgacgtatgttcccat agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttacggtaaactgc ccacttggca gtacatcaag tgtatcatat gccaagtacg ccccctattgacgtcaatga cggtaaatgg cccgcctggc attatgccca gtacatgacc ttatgggactttcctacttg gcagtacatc tacgtattag tcatcgctat taccatggtg atgcggttttggcagtacat caatgggcgt ggatagcggt ttgactcacg gggatttcca agtctccaccccattgacgt caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgtcgtaacaactc cgccccattg acgcaaatgg gcggtaggcg tgtacggtgg gaggtctatataagcagagc tcgtttagtg aaccgtc;

-   -   -   or a functional fragment thereof which functions as            promoter;

    -   b) a promoter comprising a sequence that is at least 80%,        preferably at least 85%, more preferably at least 90%, more        preferably at least 95%, more preferred at least 97%, most        preferred at least 99% identical to the sequence shown in SEQ ID        NO 8 or a functional fragment thereof which functions as        promoter.

The % identity may be calculated over the whole length of the referencesequence.

It was found that a respective promoter works particularly well incombination with the specific 5′UTR polynucleotide sequence selectedfrom the above group and the hCD33 signal sequence as is taught by thepresent invention.

The expression cassette according to the present invention furthercomprises as element b) a specific 5′UTR (five prime untranslatedregion) polynucleotide sequence. The term a “5′UTR polynucleotidesequence” as used herein in particular refers to a DNA sequence that istranscribed into mRNA but is subsequently not translated into apolypeptide. A 5′UTR polynucleotide sequence usually starts at thetranscription start site and ends before the start codon of the actualcoding region. In the expression cassette according to the presentinvention, the 5′UTR polynucleotide sequence ends before thepolynucleotide encoding the hCD33 secretory leader sequence starts.

The 5′UTR polynucleotide sequence used in the expression cassetteaccording to the present invention preferably comprises the sequenceshown in SEQ ID NO 1. A respective 5′UTR polynucleotide sequence isdescribed in WO 2009/080720.

According to one embodiment, the 5′UTR polynucleotide sequence comprisesa sequence selected from the sequences SEQ ID NO 1, SEQ ID NO 2, SEQ IDNO 3 and SEQ ID NO 4 or comprises a sequence selected from the sequencesSEQ ID NO 5, SEQ ID NO 6 or SEQ ID NO 7. The 5′ UTR sequence that isshown in SEQ ID NO 1 is a consensus sequence that is also comprised inthe 5′ UTR sequences shown as SEQ ID NO 2, 3 and 4 as well as in the5′UTR sequences shown as SEQ ID NO 5, 6 and 7. Preferably, the 5′UTRsequence comprising or consisting of SEQ ID NO 3 is used for expressingthe light chain of an antibody or a functional fragment thereof and the5′UTR sequence comprising or consisting of SEQ ID NO 1 or SEQ ID NO 4 isused for expressing the heavy chain of an antibody or a functionalfragment thereof. The 5′UTR sequence comprising or consisting of SEQ IDNO: 5 is according to one embodiment used for expressing the light chainof an antibody or a functional fragment thereof. SEQ ID NO 5 may also beused for example for the expression of a nanobody as exemplaryembodiment. The 5′UTR sequence comprising or consisting of SEQ ID NO: 6is according to one embodiment used for expressing the heavy chain of anantibody or a functional fragment thereof. The 5′UTR sequence comprisingor consisting of SEQ ID NO: 7 is according to one embodiment used forexpressing the heavy chain of an antibody or a functional fragmentthereof. It was also tested in the examples.

It was found that the 5′UTR that is used according to the presentinvention is composed of several elements and comprises an intronflanking region 5′ sequence, an intron and an intron flanking region 3′sequence. The intron and intron flanking regions comprised in said 5′UTRoriginate from mouse IgG heavy chain (see e.g. Eaton et al., 1986,Biochemistry 25, 8343-8347, Neuberger et al., 1983, EMBO J. 2(8),1373-1378; it can be obtained from the pRK-5 vector (BD PharMingen)).The following table illustrates the putative boundaries of said elementsthat are comprised in the 5′UTR that can be used according to thepresent invention:

Intron flanking region 5′ sequence (SEQ ID NO 9)agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacg cggattccccgtgccaagagtgacIntron (SEQ ID NO 10) gtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacagIntron flanking region 3′sequence (SEQ ID NO 11)gtgtccactcccaggtccaactgca

Furthermore, a 5′UTR polynucleotide sequence can be used which comprisesa sequence that is at least 85%, preferably at least 90%, preferably atleast 95%, more preferred at least 98%, most preferred at least 99%identical to the sequence shown in SEQ ID NOs 1, 2, 3 or 4 or thesequence shown in SEQ ID NO 5, SEQ ID NO 6 or SEQ ID NO 7. The identitymay be calculated over the whole length of the reference 5′UTR sequence.

In numerous experiments the inventors found that said particular 5′UTRpolynucleotide sequences have in combination with the hCD33 signalsequence the above described advantageous effects on the expressionyield which is substantially increased compared to prior art expressioncassettes.

The expression cassette according to the present invention furthercomprises as element c) a polynucleotide encoding an hCD33 secretoryleader sequence. Human CD33 is a member of the sialic acid-bindingimmunoglobulin-like lectin inhibitory receptors. CD33 is a 67-kDatransmembrane glycoprotein and is specifically expressed on the myeloidlineage. The term “a polynucleotide encoding a hCD33 secretory leadersequence” as used herein in particular refers to a polynucleotide thatencodes a secretory leader sequence comprising the hCD33 secretoryleader sequence. Thus, upon transcription and subsequent translation asecretory leader sequence is obtained which comprises and preferablyconsists of a hCD33 secretory leader sequence. Said secretory leadersequence has the effect that a polypeptide of interest fused thereto isefficiently secreted from the host cell. The secretory leader sequenceis cleaved off during biosynthesis. As discussed above, it wassurprisingly found by the inventors that the specific combination of theabove described 5′UTR polynucleotide sequence with an hCD33 secretoryleader sequence results in a remarkable increase of polypeptideexpression. Thus, the combination according to the present invention issuperior to other combinations which use the same 5′UTR in conjunctionwith other secretory leader sequences which do not comprise an hCD33secretory leader sequence but e.g. an immunoglobulin secretory leadersequence as is described in WO2009/080720. According to one embodiment,the hCD33 secretory leader sequence used in the expression cassetteaccording to the present invention comprises the following amino acidsequence:

(SEQ ID NO 12) MPLLLLLPLLWAGALA

Different amino acid sequences are described in the literature for thehCD33 secretory leader sequence. Most documents describe the hCD33secretory leader sequence as consisting of the following amino acidsequence

(SEQ ID NO 13) MPLLLLLPLLWAGALAMD.

As becomes apparent, the SEQ ID NO 13 comprises two additional aminoacids at the 3′ end compared to SEQ ID NO 12. According to oneembodiment, the polynucleotide encoding an hCD33 secretory leadersequence encodes a secretory leader sequence consisting of the aminoacid sequence shown in SEQ ID NO 12 or SEQ ID NO 13. However, it ispreferred to use the shorter hCD33 secretory leader sequence shown inSEQ ID NO 12.

The slightly shorter signal sequence is assumed to enhance theprobability of correct peptidase cleavage, enables correct processingand thereby ensures product quality. Using the longer CD33 secretoryleader sequence shown in SEQ ID NO 13 could pose the risk that thepolypeptide of interest carries additional amino acids at theirN-terminus after the secretory leader sequence is cleaved off, what isunacceptable in particular when expressing pharmaceutical polypeptides.This risk is avoided when using the hCD33 secretory leader sequenceshown in SEQ ID NO 12. Furthermore, the shorter sequence is apparentlymore efficient for secretion due to a better charge distribution, inparticular when used in combination with the 5′UTR polynucleotidesequence according to the present invention. Thus, preferably, thepolynucleotide encodes an hCD33 secretory leader sequence that consistsof the amino acid sequence shown in SEQ ID NO 12.

In the expression cassette, the promoter (element a)) is arranged 5′from the 5′UTR polynucleotide sequence (element b) which in turn isarranged 5′ from the polynucleotide encoding the hCD33 secretory leadersequence (element c)). Said elements are operably linked in theexpression cassette in order to allow an efficient expression of apolypeptide of interest if a polynucleotide encoding a respectivepolypeptide of interest is inserted into said expression cassette.

The expression cassette according to the present invention is “suitablefor expressing a polypeptide of interest”. This term in particulardescribes that a polypeptide is expressed from said expression cassetteif a polynucleotide encoding said polypeptide is inserted into saidexpression cassette. Thus, according to one embodiment the expressioncassette according to the present invention comprises as element d) apolynucleotide encoding a polypeptide of interest. Thus, saidpolynucleotide comprises the coding region of the polypeptide ofinterest. Preferably, said polynucleotide is or is derived from a cDNA.Preferably, said polynucleotide does not comprise an additionalsecretory leader sequence. Said polynucleotide encoding the polypeptideof interest is located 3′ from the polynucleotide encoding the hCD33secretory leader sequence, so that upon expression a fusion polypeptideis obtained which comprises the hCD33 secretory leader sequence and thepolypeptide of interest. The 5′UTR and the secretory leader sequencethat is used in the expression cassette according to the presentinvention are heterologous to the polynucleotide encoding thepolypeptide of interest, i.e. they are not naturally associated withsaid polynucleotide. The expression of the polynucleotide encoding thepolypeptide of interest is under the post-transcriptional control ofsaid 5′UTR and said secretory leader sequence comprising and preferablyconsisting of the hCD33 leader sequence.

According to an alternative embodiment, the expression cassettecomprises an insertion site for inserting a polynucleotide encoding apolypeptide of interest however, does not yet comprise a polynucleotideencoding a polypeptide of interest. Said insertion site is located 3′from the polynucleotide encoding the hCD33 secretory leader sequence.For this purpose the expression cassette may comprise e.g. a multiplecloning site (MCS) which can e.g. be used in all reading frames. Arespective “empty” expression cassette comprising an insertion site canbe used for inserting a polynucleotide encoding a desired polypeptide ofinterest.

This has the advantage that a customer can insert a polynucleotideencoding a desired polypeptide into said insertion site therebycompleting the expression cassette. Upon expression, the desiredpolypeptide fused to the secretory leader sequence according to thepresent invention is expressed from said completed expression cassetteand secreted. Thus, a respective “empty” expression cassette provides auseful tool for expressing different polypeptides of interest becausethe expression cassette can be easily adapted to the intended use simplyby inserting the polynucleotide encoding the desired polypeptide ofinterest into the insertion site.

Furthermore, the expression cassette may comprise an appropriatetranscription termination site. Transcription termination sites are wellcharacterized in the prior art and their incorporation in expressioncassettes has been shown to have multiple beneficial effects on geneexpression. As will be described in further detail below, the expressioncassette according to the present invention is in particular intendedfor expressing a polypeptide of interest in a eukaryotic host cell. Mosteukaryotic nascent mRNAs possess a poly A tail at their 3′ end which isadded during a complex process that involves cleavage of the primarytranscript and a coupled polyadenylation reaction. The polyA tail isinter alia advantageous for mRNA stability. Hence, the expressioncassette preferably comprises respectively provides a polyadenylationsite suitable for transcription termination and polyadenylation. Thereare several efficient polyA signals that can be used in expressioncassettes that are intended for expression in eukaryotic cells,including those derived from bovine growth hormone (bgh), mousebeta-globin, the SV40 early transcription unit and the Herpes simplexvirus thymidine kinase gene. However, also synthetic polyadenylationsites are known (see e.g. the pCl-neo expression vector of Promega whichis based on Levitt el al, 1989, Genes Dev. 3, (7): 1019-1025). Thus, thepolyadenylation site that is used in the expression cassette accordingto the present invention can be selected from the group consisting ofSV40polyA site, such as the SV40 late and early poly-A site (see e.g.plasmid pSV2-DHFR as described in Subramani et al, 1981, Mol. Cell.Biol. 854-864), a synthetic polyA site (see e.g. the pCl-neo expressionvector of Promega which is based on Levitt el al, 1989, Genes Dev. 3,(7): 1019-1025) and a bgh polyA site (bovine growth hormone). Thetranscription termination site can be provided together with thepolynucleotide encoding the polypeptide of interest or can be providedas separate element in the expression cassette.

Thus, according to one embodiment, the expression cassette furthercomprises a 3′UTR sequence as element e). A three prime untranslatedregion (3′UTR) follows the coding region and comprises regulatoryelements. Elements that may be comprised in said 3′UTR include but arenot limited to binding sites for proteins and/or molecules that induceRNAi, such as miRNAs. According to one embodiment, a 3′ UTR comprisingthe following sequence is used:

(SEQ ID NO 14) gggcggccgcttccctttagtgagggttaatgcttcgag.

Furthermore, the expression cassette may comprise a polyadenylationsignal as element f). Suitable polyadenylation sites are describedabove. According to one embodiment, a poly A site is used, comprisingthe following sequence:

(SEQ ID NO 15) cagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcattttatgtttcaggttcagggggagatgtgggaggttttttaaagcaagtaaaacctctacaaatgtggta.

According to a preferred embodiment, the expression cassette comprisesthe following elements:

-   -   a) a promoter, preferably a human CMV promoter or a promoter        derived from the human CMV promoter;    -   b) a 5′UTR polynucleotide sequence selected from the group        consisting of a 5′UTR polynucleotide sequence comprising SEQ ID        NO 1, a 5′UTR polynucleotide sequence comprising SEQ ID NO 2, a        5′UTR polynucleotide sequence comprising SEQ ID NO 3, a 5′UTR        polynucleotide sequence comprising SEQ ID NO 4, a 5′UTR        polynucleotide sequence comprising SEQ ID NO 5, a 5′UTR        polynucleotide sequence comprising SEQ ID NO 6, a 5′UTR        polynucleotide sequence comprising SEQ ID NO 7, and a 5′UTR        polynucleotide sequence comprising a sequence that is at least        85%, preferably at least 90% identical to the sequence shown in        SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5,        SEQ ID NO 6 or SEQ ID NO 7;    -   c) a polynucleotide encoding a hCD33 secretory leader sequence;    -   d) a polynucleotide encoding a polypeptide of interest or an        insertion site for inserting a polynucleotide encoding a        polypeptide of interest;    -   e) a 3′UTR polynucleotide sequence; and    -   f) a poly A site.

As described, % identity may be calculated over the whole length of thereference sequence. As discussed above and as is shown in the examples,the expression cassette according to the present invention results in anincreased expression of the polypeptide of interest. A “polypeptide”refers to a molecule comprising a polymer of amino acids linked togetherby a peptide bond(s). Polypeptides include polypeptides of any length,including proteins (for example, having more than 50 amino acids) andpeptides (for example, having 2-49 amino acids). Polypeptides includeproteins and/or peptides of any activity or bioactivity. The polypeptidethat is to be produced can be a pharmaceutically or therapeuticallyactive compound, or a research tool to be utilized in assays and thelike. A polypeptide is accordingly not limited to any particularpolypeptide or group of polypeptides, but may on the contrary be anypolypeptide, of any size, function or origin, which one desires toselect and/or express by the methods described herein. Accordingly,several different polypeptides of interest may be expressed from theexpression cassette according to the present invention and/or the hostcells according to the present invention. As is outlined above, the termpolypeptide include proteins and/or peptides of any activity orbioactivity, including e.g. bioactive polypeptides such as enzymaticproteins or peptides (e.g. proteases, kinases, phosphatases), receptorproteins or peptides, transporter proteins or peptides, bactericidaland/or endotoxin-binding proteins, structural proteins or peptides,immune polypeptides, immunoglobulins, toxins, antibiotics, hormones,growth factors, vaccines or the like. Said polypeptide may be selectedfrom the group consisting of peptide hormones, interleukins, tissueplasminogen activators, cytokines, immunoglobulins, in particularantibodies or functional fragments or derivatives thereof and singledomain antibodies, also referred to as nanobodies. According to oneembodiment, the polypeptide of interest is glycosylated. The polypeptideof interest that is expressed from the expression cassette according tothe present invention may also be a subunit or domain of one of theforegoing polypeptides, such as e.g. a heavy chain or a light chain ofan antibody or a functional fragment or derivative thereof. In apreferred embodiment the polypeptide of interest is an immunoglobulinmolecule, more preferably an antibody, or a subunit or domain thereofsuch as e.g. the heavy or light chain of an antibody or a single domainantibody. Also included are functional fragments or derivatives of theforegoing or a subunit or domain of the foregoing such as e.g. a heavyor light chain of an antibody or a functional fragment or derivativethereof. According to one embodiment, the polypeptide of interest is nothCD33.

The term “antibody” as used herein particularly refers to a proteincomprising at least two heavy chains and two light chains connected bydisulfide bonds. The term “antibody” includes naturally occurringantibodies as well as all recombinant forms of antibodies, e.g.,humanized antibodies, fully human antibodies and chimeric antibodies.Each heavy chain is usually comprised of a heavy chain variable region(VH) and a heavy chain constant region (CH). Each light chain is usuallycomprised of a light chain variable region (VL) and a light chainconstant region (CL). The heavy chain-constant region comprises threeor—in the case of antibodies of the IgM- or IgE-type—four heavychain-constant domains (CH1, CH2, CH3 and CH4) wherein the firstconstant domain CH1 is adjacent to the variable region and may beconnected to the second constant domain CH2 by a hinge region. The lightchain-constant region consists only of one constant domain. The variableregions can be further subdivided into regions of hypervariability,termed complementarity determining regions (CDRs), interspersed withregions that are more conserved, termed framework regions (FR), whereineach variable region comprises three CDRs and four FRs. The variableregions of the heavy and light chains contain a binding domain thatinteracts with an antigen. The constant regions of the antibodies maymediate the binding of the immunoglobulin to host tissues or factors,including various cells of the immune system (e.g., effector cells) andthe first component (C1q) of the classical complement system. The term“antibody” according to the invention, however, also includes othertypes and variants of antibodies such as heavy chain antibodies, i.e.antibodies only composed of one or more, in particular two heavy chains,and nanobodies, i.e. antibodies only composed of a single monomericvariable domain. Such nanobodies may also be linked to form multivalentstructures. Preferably, the antibody is upon expression in theappropriate host cell glycosylated. As discussed above, thepolynucleotide encoding the polypeptide of interest may also encode oneor more subunits or domains of an antibody, e.g. a heavy or a lightchain or a functional fragment or derivative, as polypeptide ofinterest.

A single-domain antibody, also referred to as nanobody is an antibodyfragment consisting of a single monomeric variable antibody domain. Likea whole antibody, it is able to bind selectively to a specific antigen.With a molecular weight of only 12-15 kDa, single-domain antibodies aremuch smaller than common antibodies (150-160 kDa) which are composed oftwo heavy protein chains and two light chains, and even smaller than Fabfragments and single-chain variable fragments. The first single-domainantibodies were engineered from heavy-chain antibodies found incamelids; these are called V_(H)H fragments. Heavy chain antibodies arealso found in other species. An alternative approach is to split thedimeric variable domains from common immunoglobulin G (IgG) from humansor mice into monomers. Although most research into single-domainantibodies is currently based on heavy chain variable domains,nanobodies derived from light chains have also been shown to bindspecifically to target epitopes. Antibody proteins obtained from membersof the camel and dromedary family (Camelus bactrianus and Camelusdromaderius) including new world members such as llama species (Lamapaccos, Lama glama and Lama vicugna) have been characterized withrespect to size, structural complexity and antigenicity for humansubjects. Certain IgG antibodies from this family of mammals as found innature lack light chains, and are thus structurally distinct from thetypical four chain quaternary structure having two heavy and two lightchains, for antibodies from other animals (see WO94/04678). A region ofthe camelid antibody which is the small single variable domainidentified as V_(HH) can be obtained by genetic engineering to yield asmall protein having high affinity for a target, resulting in a lowmolecular weight antibody-derived protein known as a “camelid nanobody”(see U.S. Pat. No. 5,759,808; Stijlemans, B. et al., 2004 J Biol Chem279: 1256-1261; Dumoulin, M. et al., 2003 Nature 424: 783-788;Pleschberger, M. et al. 2003 Bioconjugate Chem 14: 440-448;Cortez-Retamozo, V. et al. 2002 Int J Cancer 89: 456-62; and Lauwereys,M. et al. 1998 EMBO J 17: 3512-3520). Engineered libraries of camelidantibodies and antibody fragments are commercially available. As withother antibodies of non-human origin, an amino acid sequence of acamelid antibody can be altered recombinantly to obtain a sequence thatmore closely resembles a human sequence, i.e. the nanobody can be“humanized”. Respective single-domain antibodies can also be expressedusing the teachings of the present invention. Furthermore, as described,single-domain antibodies may also be linked to form multivalentstructures. Respective multimeric nanobodies may also be expressed usingthe teachings of the present invention. According to one embodiment, amultimeric nanobody is expressed from a single expression cassette.

A “functional fragment or derivative” of an antibody in particularrefers to a protein or glycoprotein which is derived from an antibodyand is capable of binding to the same antigen, in particular to the sameepitope as the antibody. The same applies mutatis mutandis for afragment or derivative of an immunoglobulin molecule, a heavy chain orthe light chain. It has been shown that the antigen-binding function ofan antibody can be executed by fragments of a full-length antibody orderivatives thereof. Examples of fragments or derivatives of an antibodyinclude (i) Fab fragments, monovalent fragments consisting of thevariable region and the first constant domain of each the heavy and thelight chain; (ii) F(ab)₂ fragments, bivalent fragments comprising twoFab fragments linked by a disulfide bridge at the hinge region; (iii) Fdfragments consisting of the variable region and the first constantdomain CH1 of the heavy chain; (iv) Fv fragments consisting of the heavychain and light chain variable region of a single arm of an antibody;(v) scFv fragments, Fv fragments consisting of a single polypeptidechain; (vi) (Fv)₂ fragments consisting of two Fv fragments covalentlylinked together; (vii) a heavy chain variable domain; and (viii)multibodies consisting of a heavy chain variable region and a lightchain variable region covalently linked together in such a manner thatassociation of the heavy chain and light chain variable regions can onlyoccur intermolecular but not intramolecular. These antibody fragmentsand derivatives can be obtained using conventional techniques known tothose with skill in the art.

As becomes apparent from the above described examples of polypeptidesthat can be expressed according to the teachings of the presentinvention, the final polypeptide that is to be produced and secreted bythe host cell can also be a dimeric or multimeric protein. A preferredexample of a respective protein is an immunoglobulin molecule, inparticular an antibody that comprises e.g. heavy and light chains. Thereare several options for producing a respective dimeric or multimericprotein.

According to one embodiment, two or more subunits or domains of saiddimeric or multimeric protein are expressed from one expression cassetteaccording to the present invention. In this embodiment, one longtranscript is obtained from the respective expression cassette thatcomprises the coding regions of the individual subunits or domains ofthe dimeric or multimeric protein. According to one embodiment, at leastone IRES element (internal ribosomal entry site) is functionally locatedbetween the coding regions of the individual subunits or domains andeach coding region is preceded by an hCD33 secretory leader sequence asdescribed above. Thereby, it is ensured that separate translationproducts are obtained from said transcript and that the final dimeric ormultimeric protein can be correctly assembled and secreted. Furthermore,also multimeric nanobodies can be expressed from a single expressioncassette.

However, it is also within the scope of the present invention and forsome embodiments it is even preferred to express the individual subunitsor domains of a dimeric or multimeric protein from different expressioncassettes. According to one embodiment, the expression cassetteaccording to the present invention is a monocistronic expressioncassette. In this embodiment, each expression cassette comprises apolynucleotide encoding one subunit or domain of the dimeric ormultimeric protein as polypeptide of interest. According to oneembodiment, all of these expression cassettes are designed according tothe teachings of the present invention. However, it is also within thescope of the present invention to use different designs for differentexpression cassettes. After expression of the individualsubunits/domains from the individual expression cassettes, the finaldimeric or multimeric protein is assembled and secreted from the hostcell. This embodiment will be explained in further detail in conjunctionwith the expression vector according to the present invention.

According to a preferred embodiment, the polynucleotide encoding thepolypeptide of interest encodes as polypeptide of interest the heavy orthe light chain of an antibody molecule or a functional fragment orderivative thereof.

According to one embodiment, the expression cassette according to thepresent invention already comprises a polynucleotide encoding at leastpart of a constant region of an immunoglobulin molecule. Thepolynucleotide encoding a corresponding variable part of theimmunoglobulin molecule can then be inserted by the user/customer intothe expression cassette by using appropriate cloning strategies in orderto complete the expression cassette.

The expression cassette may comprise additional elements that can beused to alleviate and/or improve the selection of high expressing hostcells. One established selection method known in the prior art forselecting host cells that express the polypeptide of interest with ahigh yield is based on the use of flow cytometry, in particularfluorescence activated cell sorting (FACS). Selection methods employingflow cytometry have the advantage that large numbers of cells can bescreened rapidly. In one selection method that is particularly useful toidentify high producing cell clones, a portion of the product ofinterest e.g. an antibody is expressed as membrane bound fusionpolypeptide. Thereby, a portion of the product is displayed as fusionpolypeptide on the cell surface. As the amount of produced fusionpolypeptide correlates with the overall expression rate, the host cellscan be selected via flow cytometry based upon the amount of fusionpolypeptide displayed on the cell surface. This allows the rapidselection of high producing host cells. The expression cassetteaccording to the present invention can be advantageously adapted so thatit can be used in a respective selection method that is based on the useof flow cytometry. To allow efficient selection using flow cytometry,preferably FACS, a special expression cassette may be used forexpressing the polypeptide of interest. Thus, according to oneembodiment, the expression cassette for expressing the polynucleotideencoding the polypeptide of interest is designed such that a portion ofthe expressed polypeptide of interest, preferably less than 10%, morepreferred less than 5% or even less than 2.5%, comprises a transmembraneanchor. Several options exist to achieve that result.

According to one embodiment, said expression cassette comprisesadditionally at least one stop codon downstream of the polynucleotideencoding the polypeptide of interest, and a further polynucleotidedownstream of the stop codon encoding a membrane anchor and/or a signalfor a membrane anchor. The respective elements are operatively linked.This design of the expression cassette has the effect that throughtranslational read-through processes (the stop codon is “leaky”) aportion of the polypeptide of interest is produced as a fusionpolypeptide comprising a membrane anchor. As a result, this fusionpolypeptide is displayed on the cell surface and cells displaying highlevels of membrane-anchored fusion polypeptide can be selected by flowcytometry, preferably by FACS. Thereby, host cells are selected thathave a high expression rate. Details and preferred embodiments of thisstop codon based technology are described in WO2005/073375 andWO2010/022961. It is referred to this disclosure.

According to an alternative embodiment said expression cassettecomprises downstream of the polynucleotide encoding the polypeptide ofinterest at least an intron comprising a 5′ splice donor site and a 3′splice acceptor site and comprising an in frame translational stop codonand a polyadenylation signal and a polynucleotide downstream of saidintron encoding a membrane anchor and/or a signal for a membrane anchor.The respective elements are operatively linked. This design of theexpression cassette has the effect that through transcription andtranscript processing at least two different mature mRNAs (mRNA-POI) and(mRNA-POI-ANCHOR) are obtained from the expression cassette. Translationof the mRNA-POI results in the product of interest. Translation of themRNA-POI-ANCHOR results in a fusion polypeptide comprising the productof interest and a membrane anchor. As a result, this fusion polypeptideis again displayed on the cell surface and cells displaying high levelsof membrane-anchored fusion polypeptide can be selected by flowcytometry, preferably FACS. Thereby, host cells are selected that have ahigh expression rate. Details and preferred embodiments of this intronbased technology are described in WO2007/131774. It is referred to thisdisclosure.

According to a preferred embodiment which is in particular useful forthe expression of antibodies as product of interest, the membrane anchoris an immunoglobulin transmembrane anchor. Other suitable membraneanchors and preferred embodiments of an immunoglobulin transmembraneanchor are described in WO2007/131774, WO2005/073375 and WO2010/022961.It is referred to the respective disclosure.

According to a second aspect, the present invention provides anexpression vector for expressing a polypeptide of interest, comprisingat least one expression cassette according to the first aspect of thepresent invention. Said expression cassette was described in detailabove, it is thus referred to the above disclosure.

An “expression vector” according to the present invention in particularrefers to a polynucleotide capable of carrying at least one foreignnucleic acid fragment. A vector functions like a molecular carrier,delivering fragments of nucleic acids respectively polynucleotides intoa host cell. It comprises at least one expression cassette according tothe first aspect of the present invention which comprises the necessaryregulatory sequences for properly expressing a polynucleotide encoding apolypeptide of interest incorporated therein.

According to one embodiment, the expression vector additionallycomprises at least one expression cassette comprising a polynucleotideencoding a selectable marker. Said expression cassette comprises thenecessary regulatory sequences for properly expressing thepolynucleotide encoding the selectable marker incorporated therein.Selectable markers include selectable markers that provide eukaryotichost cells with a resistance against toxic agents or drugs, such asantibiotics, in particular aminoglycoside antibiotics, e.g. a neomycinselectable marker. Selectable markers also include but are not limitedto eukaryotic selectable markers such as dihydrofolate reductase (DHFR)and glutamine synthetase (GS). Other suitable selection markers such asthe folic acid receptor are described in WO 2009/080759 and WO2010/097240. Preferably, the expression vector comprises at least oneexpression cassette comprising a polynucleotide encoding an amplifiableselectable marker. An amplifiable, selectable marker allows theselection of a vector-containing eukaryotic host cells as well as geneamplification. A non-limiting example for an amplifiable, selectablemammalian marker gene is the dihydrofolate reductase (DHFR) gene. Othersystems currently in use are among others the glutamine synthetase (gs)system (Bebbington et al., 1992) and the histidinol driven selectionsystem (Hartmann and Mulligan, 1988). These amplifiable markers are alsoselectable markers and can thus be used to select those cells thatobtained the vector. DHFR and glutamine synthetase provide good results.In both cases selection usually occurs in the absence of the appropriatemetabolite (hypoxanthine and thymidine in case of DHFR, glutamine in thecase of GS), thereby preventing growth of non-transformed cells. Withamplifiable systems such as the DHFR system, expression of a recombinantprotein can be increased by exposing the cells to certain agentspromoting gene amplification such as antifolates (e.g. methotrexate(MTX)) in case of the DHFR system. A suitable inhibitor for GS promotinggene amplification is methionine sulphoximine (MSX). Exposure to MSXalso results in gene amplification. According to a preferred embodiment,the expression vector comprises an expression cassette comprising apolynucleotide encoding a dihydrofolate reductase enzyme (DHFR) asselectable marker.

Furthermore, the expression vector may also comprise an expressioncassette comprising a polynucleotide encoding a prokaryotic selectablemarker. A “prokaryotic selectable marker” is a selectable markerallowing the selection in prokaryotic host cells under appropriateselection conditions. Examples of respective prokaryotic selectablemarkers are markers which provide a resistance to antibiotics such ase.g. ampicillin, kanamycin, tetracycline and/or chloramphenicol.Including a prokaryotic selectable marker in the expression vector hasthe advantage that the expression vector can be easily proliferated inprokaryotic host cells.

Preferably, the expression vector comprises at least one expressioncassette according to the first aspect of the present invention, anexpression cassette comprising a polynucleotide encoding a eukaryoticselectable marker that provides resistance against aminoglycosideantibiotics, preferably a neo selectable marker, and an expressioncassette comprising a polynucleotide encoding an amplifiable selectablemarker, preferably DHFR.

The expression vector according to the present invention can comprisemore than one expression cassette for expressing a polypeptide ofinterest. Therefore, according to one embodiment several expressioncassettes for expressing the same or different polypeptides of interestare arranged on the expression vector according to the presentinvention. Hence, the present invention also provides an expressionvector comprising more than one expression cassette wherein eachexpression cassette encodes e.g. a subunit or domain of a dimeric orhigher order multimeric protein. Expression cassettes encoding differentsubunits of a multimeric protein, each incorporated in a differentexpression cassette can be placed e.g. adjacent to each other. Formultimeric proteins encoded by at least two distinct genes (forinstance, the light and heavy chains of an antibody or functionalfragments or derivatives thereof), the polynucleotides encoding thedesired subunits or domains are inserted as polypeptides of interestinto the different expression cassettes. A respective embodiment usingat least two distinct expression cassettes for expressing individualsubunits or domains of a dimeric or multimeric protein as polypeptide ofinterest is particularly advantageous for expressing immunoglobulinmolecules such as e.g. antibodies. In the host cell, the dimeric ormultimeric protein, e.g. the antibody is assembled and secreted.According to one embodiment, the expression cassette design according tothe present disclosure is used for expressing the heavy chain of anantibody. The expression cassette of the light chain may have inembodiments a different design, e.g. it may comprise a differentsecretory leader sequence such as e.g. an Ig leader sequence. Accordingto one embodiment, both expression cassettes are designed according tothe teachings of the present disclosure.

Thus, according to one embodiment, the expression vector comprises atleast two expression cassettes according to the first aspect of thepresent invention. The polynucleotide comprised in one of saidexpression cassettes encodes the heavy chain of an immunoglobulinmolecule or a functional fragment or derivative thereof as polypeptideof interest and the polynucleotide comprised in the other expressioncassette encodes the light chain of an immunoglobulin molecule or afunctional fragment or derivative thereof as polypeptide of interest.Upon expression of the light chain and the heavy chain from saidexpression cassettes in the host cell, the functional immunoglobulinmolecule, which preferably is an antibody, is assembled and secretedfrom the host cell. According to one embodiment, the 5′ UTR for thelight chain or a functional fragment or derivative thereof comprises orconsists of the SEQ ID NO 3. According to one embodiment, the 5′ UTR forthe heavy chain or a functional fragment or derivative thereof comprisesor consists of SEQ ID NO 1 or SEQ ID NO 4. According to one embodiment,the 5′ UTR for the light chain or a functional fragment or derivativethereof comprises or consists of the SEQ ID NO 5. According to oneembodiment, the 5′ UTR for the heavy chain or a functional fragment orderivative thereof comprises or consists of SEQ ID NO 6 or SEQ ID NO 7.

Suitable expression vectors that can be used in conjunction with thepresent invention are described in WO 2009/080720, wherein, however, inthe teachings of the present invention the immunoglobulin secretoryleader sequence taught by WO 2009/080720 is replaced by the hCD33secretory leader sequence in the expression cassette(s) comprising thepolynucleotide encoding the polypeptide of interest. As described, incase more than one expression cassette is present in the expressionvector, it is sufficient that one expression cassette is designed asdescribed herein.

According to a third aspect, a eukaryotic host cell is provided,comprising at least one expression cassette according to the firstaspect of the present invention and/or comprising at least oneexpression vector according to the second aspect of the presentinvention. The expression cassette and the expression vector accordingto the present invention was described in detail above, it is referredto the above disclosure which also applies here. Preferably, theexpression cassette′ comprises a polynucleotide encoding a polypeptideof interest. A respective expression cassette preferably comprised in anexpression vector can be introduced into the host cell by transfection.

According to one embodiment, the eukaryotic host cell comprises at leasttwo expression cassettes according to the present invention. Accordingto one embodiment each of said expression cassettes comprises apolynucleotide encoding at least one subunit or domain of a dimeric ormultimeric protein as polypeptide of interest. This embodiment isparticularly suitable for expressing immunoglobulin molecules. Accordingto a preferred embodiment, the host cell comprises a first expressioncassette according to the first aspect of the present invention, whichcomprises a polynucleotide encoding the heavy chain of an immunoglobulinmolecule or a functional fragment or derivative thereof as polypeptideof interest and a second expression cassette according to the firstaspect of the present invention, which comprises a polynucleotideencoding the light chain of an immunoglobulin molecule or a functionalfragment or derivative thereof as polypeptide of interest. As discussedabove, preferably, the 5′UTR that is used in the expression cassette forexpressing the light chain comprises or consists of SEQ ID NO 3 and the5′UTR that is used in the expression cassette for expressing the heavychain comprises or consists of SEQ ID NO 1 or SEQ ID NO 4. According toone embodiment, the 5′UTR that is used in the expression cassette forexpressing the light chain comprises or consists of SEQ ID NO 5 and the5′UTR that is used in the expression cassette for expressing the heavychain comprises or consists of SEQ ID NO 6 or SEQ ID NO 7. Saidexpression cassettes can be introduced into the host cells by using oneor more appropriate expression vector(s) as described above. Accordingto one embodiment, the first expression cassette was introduced by oneexpression vector and the second expression cassette was introduced by asecond expression vector. However, it is preferred that both expressioncassettes were introduced by using one expression vector which carriesboth expression cassettes.

According to one embodiment, the eukaryotic host cell comprises at leastone expression cassette according to the first aspect for expressing theheavy chain of an antibody. As described, e.g. a 5′UTR comprising orconsisting of SEQ ID NO 1, 4, 6 or 7 may be used for this purpose.

Basically any eukaryotic host cells can be used in conjunction with thepresent invention as long as they allow the efficient expression of apolypeptide from the expression cassette according to the presentinvention. Preferably, the eukaryotic host cell is a mammalian cell.Said mammalian cell preferably is selected from the group consisting ofrodent cells, human cells and monkey cells. Particularly preferred isthe use of rodent cells, preferably selected from the group consistingof CHO cells, BHK cells, NSO cells, mouse 3T3 fibroblast cells, andSP2/0 cells. Particularly preferred is the use of CHO cells as hostcells. Human cells can be e.g. selected from the group consisting ofHEK293 cells, MCF-7 cells, PerC6 cells and HeLa cells. Monkey cells canbe selected e.g. from COS cells and Vero cells. The expression vectoraccording to the present invention is particularly suitable forproducing polypeptides in rodent cells such as CHO cells, includingDHFR″ CHO cells or DHFR⁺ CHO cells. Preferably, the host cell is a CHOcell.

According to a fourth aspect, a method is provided for producing thehost cell according to the third aspect of the present invention,wherein the expression vector according to the second aspect of thepresent invention is introduced into the eukaryotic host cell, whichpreferably is a mammalian host cell. Thereby, the expression cassetteaccording to the first aspect which preferably comprises apolynucleotide for expressing a polypeptide of interest is introducedinto the host cell.

Introduction may be achieved e.g. by transfecting the expression vectoraccording to the second aspect of the present invention. According toone embodiment, the expression vector integrates into the genome of thehost cell (stable transfection). Suitable expression vectors allowingthe introduction of the expression cassette according to the firstaspect of the present invention into the host cell are described indetail above in conjunction with the second aspect according to thepresent invention. If the introduced expression cassette is not insertedinto the genome (transient transfection) it can be lost at the laterstage e.g. when the cells undergo mitosis. Suitable expression vectorsmight also be maintained in the host cell without integrating into thegenome, e.g. by episomal replication. There are several appropriatemethods known in the prior art for introducing an expression vector intoa eukaryotic host cell, including mammalian host cells, in particular bytransfection. Respective methods include but are not limited to calciumphosphate transfection, electroporation, lipofection, biolistic- andpolymer-mediated genes transfer. Besides traditional random integrationbased methods also recombination mediated approaches can be used. Suchrecombination methods may include use of site specific recombinases likeCre, Flp or ΦC31 (see e.g. Oumard et al, Cytotechnology (2006) 50:93-108) which can mediate directed insertion of transgenes.Alternatively, the mechanism of homologous recombination might be usedto insert the expression cassette according to the present invention(reviewed in Sorrell et al, Biotechnology Advances 23 (2005) 431-469).Recombination based gene insertion allows to minimize the number ofelements to be included in the expression vector that is introduced tothe host cell. Embodiments of a suitable expression vector orcombinations of expression vectors according to the present invention aswell as suitable host cells are described in detail above; it isreferred to the above disclosure. As discussed above in conjunction withthe embodiment the expression cassettes comprising the polynucleotidesencoding the heavy chain and the light chain of an immunoglobulinmolecule or a functional fragment or derivative thereof may be locatedon the same or on different expression vectors in case a combination ofat least two expression vectors is used for transfecting the host cells.

According to a fifth aspect a method is provided for producing apolypeptide of interest, said method comprising culturing host cellsaccording to the third aspect of the present invention in a cell cultureunder conditions allowing the expression of said polypeptide ofinterest. There are two main formats of host cell cultures, namelycultures of adherent cells and suspension cultures. The use ofsuspension cultures is preferred. According to one embodiment, said hostcells are cultured under serum-free conditions.

The polypeptide of interest is expressed from the expression cassetteaccording to the present invention and is secreted from the host cell,e.g. into the culture medium, and the secreted polypeptide can beobtained therefrom. If more then one expression cassette is present inthe host cell e. g. when the dimeric or multimeric protein is expressed(see above), the dimeric or multimeric protein is assembled in the celland is then secreted from the host cell. Due to the extraordinaryexpression that is achieved by using the novel 5′UTR/secretory leadersequence combination according to the present invention, polypeptidescan be expressed and secreted with high yield. The secreted polypeptidemay also be subject to further processing steps such as e.g.purification and/or modification steps. Accordingly, the method forproducing the polypeptide of interest may comprise at least one of thefollowing steps:

-   -   isolating the polypeptide of interest from said cell culture        medium; and/or    -   processing the isolated polypeptide of interest.

Thus, the polypeptide produced in accordance with the invention may berecovered and optionally further processed, e.g. further purified,isolated and/or modified by methods known in the art. For example, thepolypeptide may be recovered from the nutrient medium by conventionalprocedures including, but not limited to, centrifugation, filtration,ultra-filtration, extraction or precipitation. Purification may beperformed by a variety of procedures known in the art including, but notlimited to, chromatography (e.g. ion exchange, affinity, hydrophobic,chromatofocusing, and size exclusion), electrophoretic procedures (e.g.,preparative isoelectric focusing), differential solubility (e.g.ammonium sulfate precipitation) or extraction.

As discussed above, the polypeptide of interest is preferably animmunoglobulin molecule or functional fragment or derivative thereof,more preferably an antibody or a functional fragment or derivativethereof.

According to a sixth aspect, the present invention pertains to the useof a 5′UTR sequence in combination with a hCD33 secretory leadersequence in an expression cassette for expressing a polypeptide ofinterest with high yield from said expression cassette, wherein said5′UTR polynucleotide sequence is selected from the group consisting of a5′UTR polynucleotide sequence comprising SEQ ID NO 1, a 5′UTRpolynucleotide sequence comprising SEQ ID NO 2, a 5′UTR polynucleotidesequence comprising SEQ ID NO 3, a 5′UTR polynucleotide sequencecomprising SEQ ID NO 4 and a 5′UTR polynucleotide sequence comprising asequence that is at least 85%, preferably at least 90% identical to thesequence shown in SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or SEQ ID NO 4or wherein said 5′UTR polynucleotide sequence is selected from the groupconsisting of a 5′UTR polynucleotide sequence comprising SEQ ID NO 5, a5′UTR polynucleotide sequence comprising SEQ ID NO 6, a 5′UTRpolynucleotide sequence comprising SEQ ID NO 7 and a 5′UTRpolynucleotide sequence comprising a sequence that is at least 85%,preferably at least 90% identical to the sequence shown in SEQ ID NO 5,SEQ ID NO 6 or SEQ ID NO 7. The identity may be calculated over thewhole length of the reference sequence.

The advantages of a respective combination, suitable and preferredembodiments of the 5′UTR polynucleotide sequence and the hCD33 secretoryleader sequence as well as suitable and preferred embodiments of theexpression cassette and the polynucleotide encoding the polypeptide ofinterest are described in detail above. It is referred to the abovedisclosure which also applies here.

Preferably, the expression cassette has the design of the expressioncassette that is described above in conjunction with the first aspect ofthe present invention. It is referred to the above disclosure. Accordingto one embodiment, the expression cassette has one or more of thefollowing characteristics:

-   a) it comprises a promoter;-   b) it comprises a 5′ UTR polynucleotide sequence as described above;-   c) it comprises a hCD33 secretory leader sequence which comprises    and preferably consists of the sequence MPLLLLLPLLWAGALA (SEQ ID NO    12);-   d) it comprises a polynucleotide encoding a polypeptide of interest    or an insertion site for inserting a polynucleotide encoding a    polypeptide of interest;-   e) it comprises a 3′UTR sequence and/or-   f) it comprises a poly A site

Details with respect to the individual elements and preferredembodiments and combinations are described above in conjunction with thefirst aspect of the present invention. It is referred to the abovedisclosure.

According to one embodiment, the polynucleotide encoding the polypeptideof interest encodes as polypeptide of interest two or more subunits ordomains of a dimeric or multimeric protein, wherein at least one IRESelement is located between the coding regions of the individual subunitsor domains and each coding region is preceded by an hCD33 secretoryleader sequence. However, the use of monocistronic expression cassettesis preferred in the context of the present invention.

According to an alternative embodiment, the polynucleotide encoding thepolypeptide of interest encodes as polypeptide of interest a subunit ordomain of a dimeric or multimeric protein. Preferably, thepolynucleotide encoding the polypeptide of interest encodes aspolypeptide of interest the heavy or the light chain of an antibodymolecule or a functional fragment or derivative thereof. According toone embodiment, an expression cassette design according to the presentdisclosure is used for expressing the heavy chain of an antibody. Here,the expression cassette for expressing the light chain may have adifferent design and may, e.g., comprise a different leader sequence,e.g. a Ig leader sequence, or may also be designed according to theteachings of the present invention. According to one embodiment, anexpression cassette design according to the present disclosure is usedfor expressing the light chain of an antibody. Here, the expressioncassette for expressing the heavy chain may have a different design andmay, e.g., comprise a different leader sequence, e.g. a Ig leadersequence, or may also be designed according to the teachings of thepresent invention.

According to one embodiment, subject-matter described herein ascomprising certain elements also refers to subject-matter consisting ofthe respective elements. In particular, the 5′UTRs described herein ascomprising certain sequences may also consist of the respectivesequences.

It is preferred to select and combine preferred embodiments describedherein and the specific subject-matter arising from a respectivecombination of preferred embodiments also belongs to the presentdisclosure.

The full content of the texts and documents as mentioned herein areincorporated herein by reference and thus form part of the presentdisclosure.

The following examples serve to illustrate the present invention withoutin any way limiting the scope thereof. In particular, the examplesrelate to preferred embodiments of the present invention.

EXAMPLES

The examples were performed according to the following protocol:

Example A I. Material and Methods

Host Cells

As host cells, CHO (Chinese Hamster Ovary) cells derived from CHO-K1cells are used.

Expression Vectors

As standard control an expression vector having a design as described inWO 2009/080720 (see in particular example 6) is used, which utilizes anIg secretory leader sequence in the expression cassettes for expressingthe antibody light and heavy chains. The CMV promoter comprised SEQ IDNO 8. SEQ ID NO 3 is used as 5′UTR for expressing the light chain andSEQ ID NO 4 was used as 5′UTR for expressing the heavy chain. Anexpression vector according to teachings of the present invention isobtained from said control vector by replacing the existing light- andheavy-chain immunoglobulin secretory leader sequence by the followinghCD33 secretory leader sequence:

(SEQ ID NO 12) MPLLLLLPLLWAGALA

Said expression vectors are used in order to express antibody molecules.A corresponding vector design is also used in order to express ananobody as polypeptide of interest, wherein, however, the 5′UTRaccording to SEQ ID NO 5 was used. Here, however, only one expressioncassette is needed. The control vector had the same design, however,again a Ig leader sequence was used.

Cell Culturing, Transfection and Selection

Cells are cultured using proprietary in-house cell culture medium, andregularly passaged 2-3 times a week to maintain in logarithmic growthphase throughout the study. The cells are transfected using standardnucleofection method. 5E6 cells/nucleofection impulse are centrifugedand resuspended in transfection buffer. 3 ug vector DNA coding for thepolypeptide of interest are added, and nucleofection is performed.Transfected cells are transferred in 125 ml shake flask, and arecultivated in shaking conditions for 24-48 hours.

A first selection step with G-418 is performed as previously describedin WO 2009/080720. Further selection is performed with 2 additionalmethotrexate (MTX) selection steps, namely 500 nM MTX, and 1000 nM MTX.Selected pools, comprising of resistant, mostly good producing cells arecloned at a density 0.5-1 cell/well, either by limiting dilution, orusing FACS system. For obtained clones, clonal productivity and growthare analysed in different screening formats.

II. Results

The experimental data obtained with the expression vector according tothe prior art (control expression vector) comprising the Ig secretoryleader sequence and the expression vector according to the presentinvention comprising the hCD33 secretory leader sequence demonstratethat the produced antibody titer is remarkable increased when using thenovel combination of the specific 5′UTR and the hCD33 secretory leadersequence according to the present invention. As protein of interest, anIgG antibody was expressed. The observed productivity increase on thepool level was on average 2.88 fold when using the expression vectoraccording to the present invention. The results could be furtherimproved on the clone level, wherein a productivity increase of 4.1 foldcould be obtained when using the expression vector according to thepresent invention (when comparing the best control clone obtained withthe control expression vector and the best clone obtained with theexpression vector according to the present invention).

When expressing a nanobody as protein of interest, comparison of thebest clones shows a productivity increase of 1.1 fold when using theexpression vector according to the present invention and when comparing6 best clones a productivity increase of 1.6 fold on average wasobtained. This is illustrated by the following tables:

TABLE 2 Novel combination evaluation with IgG antibody: A 2.88 foldproductivity increase is achieved on the pool level with the expressionvector according to the present invention. Titer (g/L) G-418 1000 nM MTXhCD33 signal 0.006 0.094 peptide Ctrl. 0.005 0.038

TABLE 3 Novel combination evaluation with IgG antibody: 4.1 foldproductivity increase comparing the best clones of the expression vectorknown in the prior art and the expression vector according to thepresent invention and in average of 6 best clones: 4 fold productivityincrease hCD33 Top 6 clones Control Top 6 clones Titer (g/L) 2.99 0.7272.69 0.656 2.65 0.642 2.21 0.622 2.12 0.575 2.11 0.503

TABLE 4 Novel combination evaluation with nanobodies: 1.1 foldproductivity increase comparing the best clones of the expression vectorknown in the prior art and the expression vector according to thepresent invention and in average of 6 best clones: 1.6 fold productivityincrease. hCD33 SP Top 6 Control Top 6 clones clones Titer 0.92 0.75(g/L) 0.92 0.58 0.90 0.57 0.88 0.57 0.88 0.57 0.87 0.57

Example B Expression Vectors

As standard control the expression vectors having the basic design asdescribed in WO 2009/080720 (see in particular example 6) were used,which utilize Ig secretory leader sequences in the expression cassettesfor expressing the antibody light and heavy chains. The expressioncassette for the heavy chain was modified using the leaky stop codontechnology described in WO2010/022961 to facilitate FACS selection. TheCMV promoter comprised SEQ ID NO 8. SEQ ID NO 5 is used as 5′UTR forexpressing the light chain and SEQ ID NO 7 is used as 5′UTR forexpressing the heavy chain. An expression vector according to teachingsof the present invention is obtained from said control vectors byreplacing the existing heavy-chain immunoglobulin secretory leadersequence by the following hCD33 secretory leader sequence:

(SEQ ID NO 12) MPLLLLLPLLWAGALA

Said expression vectors are used in order to express different antibodymolecules.

The evaluation was performed to address IgG expression and correctsignal peptide (leader sequence) processing on the heavy chain cassettefor 3 different antibodies. The correct processing of the leadersequence, i.e. leader sequence cleavage by the signal peptidase, isessential to obtain the expected sequence of the polypeptide of interestat its N-terminus, and thus a functional molecule with the expectedquality. It was noted previously that in some cases using prior artdesigns the processing of the signal peptide was incorrect, andgenerated e.g. the heavy or light chain with one or more additionalamino acids at the N-terminus. Depending on the one or more amino acidswhich incorrectly remained at the N-terminus, this extension of theamino acid sequence by the remaining one or more amino acids of theleader sequence can e.g. increase aggregation propensity of molecule orinduce disulphide bond formation. Thus, it may have a severe impact onproduct quality. Furthermore, it was found that incorrect signal peptideprocessing poses the risk that the polypeptide of interest, such as anantibody product, is cleaved by protease downstream from the predictedcleavage site at N-terminus (also referred to as clipping). Thisgenerates a truncated product, which also might have a severe impact onthe molecule quality.

Table 5 illustrates the signal peptide (leader sequence) processingresults obtained with the technology of the present disclosure comparedto the controls. As can be seen, using the technology of the inventionsignificantly reduced unwanted signal peptide processing and thusimproved the quality.

TABLE 5 Evaluation of different signal peptides on the heavy chaincassette shows improved and correct cell line processing when expressingthree different model antibodies Signal peptide Signal peptideprocessing/extensions Polypeptide processing/extensions and and clippingwith of interest clipping with hCD33 other signal peptides Antibody 1<1% ~3.6% Antibody 2 <1% ~3.2% Antibody 3 None ~1.5% ~1.2%

The invention claimed is:
 1. An expression cassette suitable forexpressing a polypeptide of interest comprising: a) a promoter; b) a5′UTR polynucleotide sequence, wherein said 5′UTR polynucleotidesequence is selected from the group consisting of i) a 5′UTRpolynucleotide sequence comprising the following sequence (SEQ ID NO 6)agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctatcgaaaaacgcgtgccgccacc;

and ii) a 5′UTR polynucleotide sequence comprising the followingsequence (SEQ ID NO 7)agatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccgcggccgggaacggtgcattggaacgcggattccccgtgccaagagtgacgtaagtaccgcctatagagtctataggcccacccccttggcttcgttagaacgcggctacaattaatacataaccttatgtatcatacacatacgatttaggtgacactatagaataacatccactttgcctttctctccacaggtgtccactcccaggtccaactgcacctcggttctat cgaaaacgcgtgccgccacc;

c) a polynucleotide encoding a hCD33 secretory leader sequence; and d) apolynucleotide encoding a polypeptide of interest or an insertion sitefor inserting a polynucleotide encoding a polypeptide of interest. 2.The expression cassette of claim 1, wherein the hCD33 secretory leadersequence consists of the sequence MPLLLLLPLLWAGALA (SEQ ID NO: 12). 3.The expression cassette of claim 1, wherein said expression cassettefurther comprises e) a 3′UTR sequence and/or f) a poly A signal.
 4. Theexpression cassette of claim 1 wherein the polynucleotide encoding thepolypeptide of interest encodes as polypeptide of interest, two or moresubunits or domains of a dimeric or multimeric protein, wherein at leastone IRES element is located between the coding regions of the individualsubunits or domains and each coding region is preceded by an hCD33secretory leader sequence.
 5. An expression vector for expressing apolypeptide of interest, comprising at least one expression cassette ofclaim 1, additionally comprising one or more of the following elements:a) at least one expression cassette comprising a polynucleotide encodinga selectable marker; b) at least one second expression cassette forexpressing a polypeptide of interest.
 6. A eukaryotic host cellcomprising at least one expression cassette of claim
 1. 7. The host cellof claim 6, wherein said host cell is selected from the group consistingof rodent cells, primate cells and human cells and wherein said hostcell preferably is a CHO cell.
 8. A method for producing a polypeptideof interest, said method comprising culturing the eukaryotic host cellsof claim 6 in a cell culture under conditions allowing expression ofsaid polypeptide of interest.
 9. The method of claim 8, wherein saidpolypeptide of interest is secreted into the cell culture medium and isisolated from the cell culture medium and the isolated polypeptide isoptionally further processed.
 10. The method of claim 8, wherein saidpolypeptide is an immunoglobulin molecule or fragment thereof.
 11. Theexpression cassette of claim 1, wherein the polynucleotide encoding thepolypeptide of interest encodes as polypeptide of interest, two or moresubunits or domains of a dimeric or multimeric protein, wherein at leastone IRES element is located between the coding regions of the individualsubunits or domains and each coding region is preceded by an hCD33secretory leader sequence.
 12. The expression cassette of claim 1,wherein the expression cassette is a monocistronic expression cassette.13. The expression cassette of claim 1 wherein the 5′UTR polynucleotidesequence comprises SEQ ID NO:
 6. 14. The expression cassette of claim 1wherein the 5′UTR polynucleotide sequence comprises SEQ ID NO: 7.